What is Invitae?
Invitae is a medical genetics company founded in 2010 and headquartered in San Francisco, California. The company specializes in providing comprehensive genetic testing services. This involves processing DNA-extracted samples from at-home test kits, analyzing patient-specific genetic variations, and generating detailed reports for clinicians and their patients across the United States. Invitae's mission is to make genetic information more accessible and actionable, thereby improving healthcare outcomes and advancing personalized medicine.
How much funding has Invitae raised?
Invitae has raised a total of $1.2B across 11 funding rounds:
Series F
$120M
Stock Offering
$116.8M
Share Placement
$73.5M
Debt
$40M
Stock Offering
$53.5M
Stock Offering
$196.7M
Debt
$291.2M
Stock Offering
$184M
Share Placement
$30M
Series F (2014): $120M supported by Wellington Management, OrbiMed, Decheng Capital, Genesys Capital, Genomic Health, The Broe Group, Perceptive Advisors, Redmile Group, Rock Springs Capital, Thomas McNerney & Partners, Deerfield, Randy Scott, and Casdin Capital
Stock Issuance/Offering (2015): $116.8M featuring Undisclosed
Share Placement (2017): $73.5M backed by Undisclosed
Debt (2018): $40M with participation from Oxford Finance
Stock Issuance/Offering (2018): $53.5M led by Undisclosed
Stock Issuance/Offering (2019): $196.7M supported by Undisclosed
Debt (2019): $291.2M featuring Undisclosed
Stock Issuance/Offering (2020): $184M backed by Undisclosed
Share Placement (2023): $30M, investors not publicly disclosed
Key Investors in Invitae
Genesys Capital
Genesys Capital is a venture capital firm based in Toronto, with a strategic focus on early-stage life sciences and healthcare companies, actively investing in biotechnology and medical innovation across North America.
OrbiMed
OrbiMed is a specialized investment firm dedicated to the healthcare sector, managing capital across biopharmaceuticals, medical devices, digital health, and diagnostics, with a deep understanding of healthcare innovation cycles.
Decheng Capital
Decheng Capital is a global investment firm established in 2012, focusing on providing capital and strategic support to early-stage life science and growth-stage healthcare companies, aiming to build leading companies through revolutionary technologies.
What's next for Invitae?
The recent major strategic investment indicates Invitae's continued focus on scaling its operations and potentially expanding its service offerings or geographic reach. Given the enterprise-level nature of its total funding, Invitae is likely in a phase of significant commercial expansion and market penetration. Future strategic moves may involve further technological advancements in genetic analysis, partnerships to broaden clinical adoption, or exploring new applications for genetic data in disease management and prevention. The company's trajectory suggests a commitment to solidifying its leadership in the rapidly evolving field of genetic diagnostics.
See full Invitae company page
